Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism

Journal of Pharmacology and Experimental Therapeutics

Volumn 291, Issue 2, 1999, Pages 749-759

  Mei, Qin ^a   Tang, Cuyue ^a   Assang, Carol ^a   Lin, Yuh ^a   Slaughter, Donald ^a   Rodrigues, A David ^a   Baillie, Thomas A ^a   Rushmore, Thomas H ^a   Shou, Magang ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORZOXAZONE; CYTOCHROME P450; CYTOCHROME P450 3A4; DEBRISOQUINE 4 HYDROXYLASE; DIAZEPAM; DIMETHYLNITROSAMINE DEMETHYLASE; ETHOXYRESORUFIN DEETHYLASE; KETOCONAZOLE; MEPHENYTOIN; MONOCLONAL ANTIBODY; PHENACETIN O DEETHYLASE; TESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG CROSS REACTIVITY; DRUG METABOLISM; DRUG RESEARCH; DRUG SELECTIVITY; ENZYME MECHANISM; ENZYME POLYMORPHISM; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN TISSUE; HYBRIDOMA; LEPIDOPTERA; LIVER MICROSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CROSS REACTIONS; CYTOCHROME P-450 ENZYME SYSTEM; DIAZEPAM; DNA, COMPLEMENTARY; DOGS; FEMALE; HAPLORHINI; HUMANS; KETOCONAZOLE; MALE; MICE; MICROSOMES, LIVER; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHARMACEUTICAL PREPARATIONS; PHENOTYPE; PROTEIN BINDING; RATS; SPECIES SPECIFICITY; SPODOPTERA; TESTOSTERONE;

EID: 0032723284     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Bourrie M, Meunier V, Berger Y and Gabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332.
2. Coon MJ, Ding XX, Pernecky SJ and Vaz AD (1992) Cytochrome P450: Progress and predictions. FASEB J 6:669-673.
3. Crespi CL, Steimel DT, Penman BW, Korzekwa KR, Fernandez Salguero P, Buters JT, Gelboin HV, Gonzalez FJ, Idle JR and Daly AK (1995) Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374. Pharmacogenetics 5:234-243.
4. Eagling VA, Tjia JF and Back DJ (1998) Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 45:107-114.
5. Edwards RJ, Adams DA, Watts PS, Davies DS and Boobis AR (1998) Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans. Biochem Pharmacol 56:377-387.
6. Ekins S, Vandenbrande M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV and Wrighton SA (1998) Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther 286:1253-1259.
7. Ey PL, Prowse SJ and Jenkin CR (1978) Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-Sepharose. Immunochemistry 16:429-436.
8. Friedman FK, Wiebel FJ, and Gelboin HV (1985) Modulation of rat hepatic aryl hydrocarbon hydroxylase by various flavones and polycyclic aromatic hydrocarbons. Pharmacology 31:194-202.
9. Gelboin HV (1993) Cytochrome P450 and monoclonal antibodies. Pharmacol Rev 45:413-453.
10. Gelboin HV, Krausz KW, Goldfarb I, Buters JT, Yang SK, Gonzalez FJ, Korzekwa KR and Shou M (1995) Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4. Biochem Pharmacol 50:1841-1850.
11. Gelboin HV, Park SS and Battula N (1988) DNA recombinant and monoclonal antibody directed methods for determining cytochrome P-450 specificity. Biochem Pharmacol 37:98-102.
12. Goldfarb I, Korzekwa K, Krausz KW, Gonzalez F and Gelboin HV (1993) Cross-reactivity of thirteen monoclonal antibodies with ten vaccinia cDNA expressed rat, mouse and human cytochrome P450s. Biochem Pharmacol 46:787-790.
13. Goldstein JA, Faletto MB, Romkes Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM and Ghanayem BI (1994) Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33:1743-1752.
14. Gonzalez FJ (1988) The molecular biology of cytochrome P450s [published erratum appears in Pharmacol Rev (1989) 41:91-92]. Pharmacol Rev 40:243-288.
15. Gonzalez FJ, Kimura S, Tamura S and Gelboin HV (1991) Expression of mammalian cytochrome P450 using baculovirus. Methods Enzymol 206:93-99.
16. Guengerich FP (1992) Metabolic activation of carcinogens. Pharmacol Ther 64:17-61.
17. Guengerich FP, Shimada T, Bondon A and Macdonald TL (1991) Cytochrome P-450 oxidations and the generation of biologically reactive intermediates. Adv Exp Med Biol 283:1-11.
18. Halpert JR, Guengerich FP, Bend JR and Correia MA (1994) Selective inhibitors of cytochromes P450. Toxicol Appl Pharmacol 125:163-175.
19. Hanioka N, Korzekwa K and Gonzalez FJ (1990) Sequence requirements for cytochromes P450IIA1 and P450IIA2 catalytic activity: Evidence for both specific and non-specific substrate binding interactions through use of chimeric cDNAs and cDNA expression. Prot Eng 3:571-575.
20. Hostetler KA, Wrighton SA, Kremers P and Guzelian PS (1987) Immunochemical evidence for multiple steroid-inducible hepatic cytochromes P-450 in the rat. Biochem J 245:27-33.
21. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC and Nebert DW (1996) P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
22. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP and Yang CS (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1 [published erratum appears in Chem Res Toxicol (1991) 4:389]. Chem Res Toxicol 3:566-573.
23. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ and Harris JW (1994) Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54:5543-5556.
24. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465-480.
25. Ryan DE, Thomas PE, Levin W, Maines SL, Bandiera S and Reik LM (1993) Monoclonal antibodies of differentiating specificities as probes of cytochrome P450h (2C11). Arch Biochem Biophys 301:282-293.
26. Sai Y, Dai R, Yang TJ, Gonzalez FJ, Gelboin HG, and Shou M (1998) Inhibition kinetics of monoclonal antibodies against cytochrome P450-mediated drug metabolism. FASEB J 12:A146.
27. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
28. Shou M, Korzekwa KR, Brooks EN, Krausz KW, Gonzalez FJ and Gelboin HV (1997) Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis 18:207-214.
29. Shou M, Korzekwa KR, Krausz KW, Crespi CL, Gonzalez FJ and Gelboin HV (1994) Regio- and stereo-selective metabolism of phenanthrene by twelve cDNA-expressed human, rodent, and rabbit cytochromes P-450. Cancer Lett 83:305-313.
30. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ and Gelboin HV (1998) Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: Enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8:391-401.
31. Thomas PE, Reik LM, Maines SL, Bandiera S, Ryan DE and Levin W (1986) Antibodies as probes of cytochrome P450 isozymes. Adv Exp Med Biol 197:95-106.
32. Tracy TS, Rosenbluth BW, Wrighton SA, Gonzalez FJ and Korzekwa KR (1995) Role of cytochrome P450 2C9 and an allelic variant in the 4′-hydroxylation of (R)- and (S)-flurbiprofen. Biochem Pharmacol 49:1269-1275.
33. Wang PP, Beaune P, Kaminsky LS, Dannan GA, Kadlubar FF, Larrey D and Guengerich FP (1983) Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. Biochemistry 22:5375-5383.
34. Wang RW and Lu AY (1997) Inhibitory anti-peptide antibody against human CYP3A4. Drug Metab Dispos 25:762-767.
35. Wang RW, Newton DJ, Liu NY, Shou M, Rushmore TH and Lu AYH (1999) Inhibitiory anti-CYP3A4 peptide antibody: Mapping of inhibitiory epitope and specificity toward other CYP3A isoforms. Drug Metab Dispos 27:167-172.
36. Wrighton SA and Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:1-21.
37. Yamazaki H, Inui Y, Yun CH, Guengerich FP and Shimada T (1992) Ctyochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13:1789-1794.
38. Yang TJ, Shou M, Korzekwa KR, Gonzalez FJ, Gelboin HV and Yang SK (1998) Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam. Biochem Pharmacol 55:889-896.
39. Yun CH, Shimada T and Guengerich FP (1991) Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol Pharmacol 40:679-685.